maxsort_date=41416.404676;
batchsize=3;
event_count=7;
year=2013;
month=5;
day=24;
hour=14;
minute=22;
second=25;
event_date=2013-05-20 16:27:03;
sort_date=41414.685451;
Chief Pulse Comment by Anthony C Hooper
As the latest move,
Amgen Inc plans to form a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma Co to bring its colon cancer drug Vectibix to the Chinese market.
"This joint venture brings us one step closer to providing Chinese patients with Amgen's medicines and supports our strategy of expanding in key, fast growing markets," said Anthony Hooper, executive vice president at Amgen. The joint venture will be named
Amgen Beta Pharmaceuticals Co, in which
Amgen owns 49 percent of interest. Vectibix is a prescription medicine used for the treatment of metastatic colorectal cancer.
Share:
As the latest move, <span class="company">Amgen</span> Inc plans to form a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma Co to bring its colon cancer drug Vectibix to the Chinese market. <span class="sent">"This joint venture brings us one step closer to providing Chinese patients with <span class="company">Amgen</span>'s medicines and supports our strategy of expanding in key, fast growing markets," said <span class="analyst">Anthony Hooper</span>, executive vice president at <span class="company">Amgen</span>.</span> The joint venture will be named <span class="company">Amgen</span> Beta Pharmaceuticals Co, in which <span class="company">Amgen</span> owns 49 percent of interest. Vectibix is a prescription medicine used for the treatment of metastatic colorectal cancer.
Tweet this
read full story
event_date=2013-05-20 15:13:15;
sort_date=41414.634201;
Talk about contrasting fortunes: So far this year, Apple ( AAPL ) stock has fallen 17% while Amgen (
AMGN ) is up 18%. But it's not just some nice symmetry in those moves , investors can also learn something about sector valuations.
That's the argument made by Lazard Capital Markets analysts Joshua Schimmer and Edward Parker in a note today, who use the differing performances of the two stocks to make a wider point about sector rotation from technology to biotech, and what the future may hold for the latter.
Share:
Talk about contrasting fortunes: So far this year, Apple ( AAPL ) stock has fallen 17% while Amgen ( <span class="company">AMGN</span> ) is up 18%. But it's not just some nice symmetry in those moves , investors can also learn something about sector valuations.<span class="sent"> That's the argument made by Lazard Capital Markets analysts Joshua Schimmer and <span class="analyst">Edward Parker</span> in a note today, who use the differing performances of the two stocks to make a wider point about sector rotation from technology to biotech, and what the future may hold for the latter.</span>...Talk about contrasting fortunes: So far this year, Apple ( AAPL ) stock has fallen 17% while Amgen ( <span class="company">AMGN</span> ) is up 18%. But it's not just some nice symmetry in those moves , investors can also learn something about sector valuations.<span class="sent"> That's the argument made by Lazard Capital Markets analysts Joshua Schimmer and <span class="analyst">Edward Parker</span> in a note today, who use the differing performances of the two stocks to make a wider point about sector rotation from technology to biotech, and what the future may hold for the latter.</span> Tweet this
read full story
event_date=2013-05-13 04:50:11;
sort_date=41407.201516;
Chief Pulse Comment by Anthony C Hooper
According to the press release , its establishment is subject to the satisfaction of certain closing conditions, including the approval of relevant government authorities in China."This
joint venture brings us one step closer to providing Chinese patients with Amgen's medicines and supports our strategy of expanding in key, fast growing markets," said Anthony C. Hooper, executive vice president at Amgen, in a press statement ."Our partnership with
Amgen will be of long term strategic significance not only for Zhejiang Province, but also for the whole medical community in China," said Lieming Ding, chairman of Zhejiang Beta Pharma. "We share
Amgen's passion for developing molecularly targeted therapies for unmet medical needs, and are confident that together we can help many Chinese patients who suffer from colorectal cancer.".
Share:
According to the press release , its establishment is subject to the satisfaction of certain closing conditions, including the approval of relevant government authorities in China."This <span class="sent">joint venture brings us one step closer to providing Chinese patients with <span class="company">Amgen</span>'s medicines and supports our strategy of expanding in key, fast growing markets," said Anthony C. Hooper, executive vice president at <span class="company">Amgen</span>, in a press statement ."Our</span> partnership with <span class="company">Amgen</span> will be of long term strategic significance not only for Zhejiang Province, but also for the whole medical community in China," said Lieming Ding, chairman of Zhejiang Beta Pharma. "We share <span class="company">Amgen</span>'s passion for developing molecularly targeted therapies for unmet medical needs, and are confident that together we can help many Chinese patients who suffer from colorectal cancer.". Tweet this
read full story
event_date=2013-05-10 12:37:21;
sort_date=41404.525938;
Chief Pulse Comment by Anthony C Hooper
Zhejiang Beta Pharma's China capabilities are complementary to
Amgen's global expertise in the development and manufacturing of human therapeutics.
"This joint venture brings us one step closer to providing Chinese patients with Amgen's medicines and supports our strategy of expanding in key, fast growing markets," said Anthony C. Hooper, executive vice president at Amgen. "We are pleased to have the opportunity to join forces with Zhejiang Beta Pharma, a leader in developing and commercializing innovative medicines that shares our goal of making a new treatment option available to colorectal cancer patients in China.". "
Amgen is a pioneer and a global leader in the biotech industry. Our partnership with
Amgen will be of long term strategic significance not only for Zhejiang Province, but also for the whole medical community in China," said Lieming Ding, chairman of Zhejiang Beta Pharma.
Share:
Zhejiang Beta Pharma's China capabilities are complementary to <span class="company">Amgen</span>'s global expertise in the development and manufacturing of human therapeutics. <span class="sent">"This joint venture brings us one step closer to providing Chinese patients with <span class="company">Amgen</span>'s medicines and supports our strategy of expanding in key, fast growing markets," said Anthony C. Hooper, executive vice president at <span class="company">Amgen</span>.</span> "We are pleased to have the opportunity to join forces with Zhejiang Beta Pharma, a leader in developing and commercializing innovative medicines that shares our goal of making a new treatment option available to colorectal cancer patients in China.". "<span class="company">Amgen</span> is a pioneer and a global leader in the biotech industry. Our partnership with <span class="company">Amgen</span> will be of long term strategic significance not only for Zhejiang Province, but also for the whole medical community in China," said Lieming Ding, chairman of Zhejiang Beta Pharma. Tweet this
read full story
event_date=2013-04-24 16:46:27;
sort_date=41388.698924;
Analyst Comment by
Deutsche BankTarget price raised from $ 108.00 to $ 115.00
Analyst Comment by
BMO Capital MarketsBMO Capital Markets reiterates market perform rating on Amgen, Inc.
event_date=2013-04-24 08:03:17;
sort_date=41388.335613;
Amgen Inc. (AMGN) had
1 more Street Pulse
events during the past 90 days. Register for a
free trial of Alacra PulsePro to see all these events.
